Haritaki for Anti-Inflammatory

Research suggests that Haritaki and formulations containing it, particularly Triphala, demonstrate anti-inflammatory properties across a range of laboratory, animal, and limited clinical contexts. The available evidence consists primarily of narrative reviews, in vitro studies, animal models, and a small number of human trials, with one notable randomized, double-blind, placebo-controlled study on Terminalia chebula extract showing modest effects on skin-related inflammatory markers such as redness. Studies indicate that key bioactive compounds in Haritaki, including chebulic acid, chebulagic acid, and chebulinic acid, may underlie these effects through antioxidant and free radical-neutralizing mechanisms, and that protease inhibition observed in laboratory testing suggests potential relevance to inflammatory conditions like oral disease. However, most findings come from preclinical or review-level evidence rather than rigorous human clinical trials, and much of the research examines Haritaki as part of multi-herb formulations rather than in isolation, making it difficult to attribute specific anti-inflammatory effects to Haritaki alone; reviewers consistently call for more controlled human studies before firm conclusions can be drawn.